Abstract
In this multicenter study of 100 patients with cervical dystonia, we examined the immunogenicity of botulinum toxin type B (BTX-B) and correlated the clinical response with the presence of blocking antibodies (Abs) using a novel mouse protection assay. One-third of the patients who were negative for BTX-B Abs at baseline became positive for BTX-B Abs at last visit. Thus, the high antigenicity of BTX-B limits its long-term efficacy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2233-2235 |
| Number of pages | 3 |
| Journal | Neurology |
| Volume | 67 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 1 2006 |
ASJC Scopus subject areas
- Clinical Neurology
Fingerprint Dive into the research topics of 'Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia'. Together they form a unique fingerprint.
Cite this
Jankovic, J., Hunter, C., Dolimbek, B. Z., Dolimbek, G. S., Adler, C. H., Brashear, A., Comella, C. L., Gordon, M., Riley, D. E., Sethi, K. D., Singer, C., Stacy, M., Tarsy, D., & Atassi, M. Z. (2006). Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology, 67(12), 2233-2235. https://doi.org/10.1212/01.wnl.0000249308.66959.43